This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Fidanacogene elaparvovec for haemophilia B

< Back

Fidanacogene elaparvovec for haemophilia B


Haematology and Blood Products

October 2021

Fidanacogene elaparvovec in development for the treatment of moderately severe or severe haemophilia B in adult males. Haemophilia B is a hereditary bleeding disorder that results in the blood taking longer to clot than normal. The disorder is caused by having a faulty version of the F9 gene. The F9 gene provides instructions for making a protein called coagulation factor IX which is released following injury to a blood vessel to form a clot and prevent further blood loss. A faulty F9 gene results in insufficient production of functional clotting factor protein IX. In severe cases, this can result in spontaneous bleeding into the joints, muscles or brain causing serious complications.
Fidanacogene elaparvovec is a medicinal product administered intravenously. Fidanacogene elaparvovec is a gene therapy that delivers a copy of the gene that encodes for factor IX in a patient’s liver cells. Through this, this medicinal product helps to maintain a sustained level factor IX in the blood of adult male with haemophilia B. If licensed, Fidanacogene elaparvovec will offer an additional treatment option for adult males with moderately severe or severe haemophilia B.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts